Conmed Corp share price today

(CNMD)

Conmed Corp share price is $74.69 & ₹6,324.90 as on 10 Dec 2024, 2.30 'hrs' IST

$74.69

▲

2.45

(3.39%)

Market is closed - opens 8 PM, 10 Dec 2024

View live Conmed Corp share price in Dollar and Rupees. Guide to invest in Conmed Corp from India. Also see the sentimental analysis on Indian investors investing in Conmed Corp. Get details on the Indian mutual funds that are investing in Conmed Corp. Get Analyst recommendations and forecasts along with all the Conmed Corp's financials.

Conmed Corp share price movements

$72.93
$74.93
$74.69
2.36%
Downside
Day's Volatility :2.67%
Upside
0.32%
$61.05
$117.27
$74.69
18.26%
Downside
52 Weeks Volatility :47.94%
Upside
36.31%

Conmed Corp Returns

Period	Conmed Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	0.76%	-6.4%	0.0%
6 Months	-2.33%	-0.9%	0.0%
1 Year	-33.05%	9.9%	0.0%
3 Years	-46.89%	8.2%	-20.3%

Conmed Corp Key Statistics

in dollars & INR

Previous Close	$72.24
Open	$72.33
Today's High	$74.93
Today's Low	$72.93
Market Capitalization	$2.3B
Today's Volume	$366.2K
52 Week High	$117.27
52 Week Low	$61.05
Revenue TTM	$1.3B
EBITDA	$217.8M
Earnings Per Share (EPS)	$4.15
PE Ratio	17.49
Dividend Yield	1.08%
Profit Margin	10.23%
Quarterly Earnings Growth YOY	2.14%
Return On Equity TTM	15.24%

How to invest in Conmed Corp from India?

It is very easy for Indian residents to invest directly in Conmed Corp from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Conmed Corp stock in both rupees (INR) and dollars (USD). Search for Conmed Corp or CNMD on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Conmed Corp or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Conmed Corp shares which would translate to 0.011 fractional shares of Conmed Corp as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Conmed Corp

150%

Period: Sep 10, 2024 to Dec 9, 2024. Change in 30 Days versus previous period

Search volume for Conmed Corp on INDmoney from India has grown in the last 30 days as on Dec 10, 2024. 150% more investors are searching Conmed Corp in the last 30 days versus the previous period.

Global Institutional Holdings in Conmed Corp

BlackRock Inc
16.17%
Vanguard Group Inc
11.43%
Earnest Partners LLC
9.01%
Capital Research Global Investors
5.00%
Champlain Investment Partners, LLC
4.43%
Bank of America Corp
4.28%

Analyst Recommendation on Conmed Corp

Buy

71%Buy

28%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Conmed Corp(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Conmed Corp

What analysts predicted

Upside of 11.29%

Current:

$74.69

Target:

$83.13

Insights on Conmed Corp

Price Movement
In the last 1 year, CNMD stock has moved down by -33.6%
Decreasing Revenue
Revenue is down for the last 2 quarters, 330.74M → 316.70M (in $), with an average decrease of 4.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 19.70M → 48.98M (in $), with an average increase of 36.5% per quarter
CNMD vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 64.7% return, outperforming this stock by 98.3%
CNMD vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 119.3% return, outperforming this stock by 166.7%
Price to Sales
ForCNMD every $1 of sales, investors are willing to pay $1.7, whereas for Boston Scientific Corp., the investors are paying $8.3 for every $1 of sales.

Conmed Corp Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$859.6M	↑ 7.94%
Net Income	$40.9M	↓ 26.37%
Net Profit Margin	4.75%	↓ 2.22%

	FY19	Y/Y Change
Revenue	$955.1M	↑ 11.11%
Net Income	$28.6M	↓ 29.95%
Net Profit Margin	3.0%	↓ 1.75%

	FY20	Y/Y Change
Revenue	$862.5M	↓ 9.7%
Net Income	$9.5M	↓ 66.75%
Net Profit Margin	1.1%	↓ 1.9%

	FY21	Y/Y Change
Revenue	$1.0B	↑ 17.18%
Net Income	$62.5M	↑ 557.16%
Net Profit Margin	6.19%	↑ 5.09%

	FY22	Y/Y Change
Revenue	$1.0B	↑ 3.45%
Net Income	$-80.6M	↓ 228.84%
Net Profit Margin	-7.71%	↓ 13.9%

	FY23	Y/Y Change
Revenue	$1.2B	↑ 19.06%
Net Income	$64.5M	↓ 179.99%
Net Profit Margin	5.18%	↑ 12.89%

	Q2 FY23	Q/Q Change
Revenue	$317.7M	↑ 7.51%
Net Income	$13.7M	↑ 654.92%
Net Profit Margin	4.32%	↑ 3.7%

	Q3 FY23	Q/Q Change
Revenue	$304.6M	↓ 4.12%
Net Income	$15.8M	↑ 15.33%
Net Profit Margin	5.2%	↑ 0.88%

	Q4 FY23	Q/Q Change
Revenue	$327.0M	↑ 7.38%
Net Income	$33.1M	↑ 108.82%
Net Profit Margin	10.11%	↑ 4.91%

	Q1 FY24	Q/Q Change
Revenue	$311.6M	↓ 4.71%
Net Income	$19.7M	↓ 40.4%
Net Profit Margin	6.32%	↓ 3.79%

	Q2 FY24	Q/Q Change
Revenue	$330.7M	↑ 6.13%
Net Income	$30.0M	↑ 52.09%
Net Profit Margin	9.06%	↑ 2.74%

	Q3 FY24	Q/Q Change
Revenue	$316.7M	↓ 4.25%
Net Income	$49.0M	↑ 63.41%
Net Profit Margin	15.47%	↑ 6.41%

	FY18	Y/Y Change
Total Assets	$1.4B	↑ 0.82%
Total Liabilities	$706.9M	↓ 2.71%

	FY19	Y/Y Change
Total Assets	$1.8B	↑ 29.65%
Total Liabilities	$1.1B	↑ 50.61%

	FY20	Y/Y Change
Total Assets	$1.8B	↓ 1.32%
Total Liabilities	$1.0B	↓ 2.07%

	FY21	Y/Y Change
Total Assets	$1.8B	↑ 0.82%
Total Liabilities	$980.6M	↓ 5.95%

	FY22	Y/Y Change
Total Assets	$2.3B	↑ 30.1%
Total Liabilities	$1.6B	↑ 58.28%

	FY23	Y/Y Change
Total Assets	$2.3B	↑ 0.11%
Total Liabilities	$1.5B	↓ 5.56%

	Q2 FY23	Q/Q Change
Total Assets	$2.3B	↑ 0.11%
Total Liabilities	$1.5B	↓ 1.6%

	Q3 FY23	Q/Q Change
Total Assets	$2.3B	↑ 0.13%
Total Liabilities	$1.5B	↓ 0.85%

	Q4 FY23	Q/Q Change
Total Assets	$2.3B	↓ 1.1%
Total Liabilities	$1.5B	↓ 4.16%

	Q1 FY24	Q/Q Change
Total Assets	$2.3B	↑ 0.4%
Total Liabilities	$1.5B	↓ 0.76%

	Q2 FY24	Q/Q Change
Total Assets	$2.3B	↓ 1.02%
Total Liabilities	$1.4B	↓ 3.49%

	Q3 FY24	Q/Q Change
Total Assets	$2.3B	↑ 1.32%
Total Liabilities	$1.4B	↓ 1.49%

	FY18	Y/Y Change
Operating Cash Flow	$74.7M	↑ 13.93%
Investing Cash Flow	$-16.5M	↓ 43.19%
Financing Cash Flow	$-72.3M	↑ 107.18%

	FY19	Y/Y Change
Operating Cash Flow	$95.1M	↑ 27.35%
Investing Cash Flow	$-387.7M	↑ 2248.47%
Financing Cash Flow	$300.9M	↓ 516.36%

	FY20	Y/Y Change
Operating Cash Flow	$64.5M	↓ 32.17%
Investing Cash Flow	$-13.6M	↓ 96.48%
Financing Cash Flow	$-52.1M	↓ 117.3%

	FY21	Y/Y Change
Operating Cash Flow	$111.8M	↑ 73.2%
Investing Cash Flow	$-14.9M	↑ 9.0%
Financing Cash Flow	$-101.5M	↑ 95.06%

	FY22	Y/Y Change
Operating Cash Flow	$33.4M	↓ 70.15%
Investing Cash Flow	$-249.5M	↑ 1578.52%
Financing Cash Flow	$225.0M	↓ 321.57%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$26.7M	↓ 793.35%
Investing Cash Flow	$-5.5M	↑ 29.97%
Financing Cash Flow	$-19.8M	↓ 469.85%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$46.1M	↑ 72.94%
Investing Cash Flow	$-5.4M	↓ 2.44%
Financing Cash Flow	$-37.2M	↑ 88.15%

Conmed Corp Technicals Summary

Sell

Neutral

Buy

Conmed Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Conmed Corp Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Conmed Corp	-3.03%	-2.33%	-33.05%	-46.89%	-47.57%
Stryker Corporation	0.95%	10.41%	30.52%	47.06%	91.45%
Boston Scientific Corp.	2.32%	17.34%	63.83%	118.51%	102.66%
Edwards Lifesciences Corp.	8.59%	-16.75%	3.02%	-40.01%	-5.81%
Abbott Laboratories	-1.04%	9.24%	8.82%	-14.98%	34.45%
Medtronic Plc	-4.68%	2.67%	5.54%	-25.45%	-25.13%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Conmed Corp	17.49	17.49	5.29	4.03	0.15	0.04	0.01	30.21
Stryker Corporation	40.99	40.99	2.67	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	74.82	74.82	1.64	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	28.63	28.63	6.78	2.52	0.19	0.11	NA	16.18
Abbott Laboratories	35.24	35.24	2.25	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	26.38	26.38	1.56	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Conmed Corp	Buy	$2.3B	-47.57%	17.49	10.23%
Stryker Corporation	Buy	$145.8B	91.45%	40.99	16.34%
Boston Scientific Corp.	Buy	$133.9B	102.66%	74.82	11.26%
Edwards Lifesciences Corp.	Buy	$42.7B	-5.81%	28.63	65.86%
Abbott Laboratories	Buy	$201.1B	34.45%	35.24	13.99%
Medtronic Plc	Buy	$110.6B	-25.13%	26.38	12.06%

Conmed Corp Dividend announcements

Conmed Corp Dividends September, 2024
In the quarter ending September,2024. Conmed Corp has declared dividend of $0.20
Read More

About Conmed Corp

conmed corporation is a global medical technology company that specializes in the development and sale of surgical and patient monitoring products and services that allow our physician customers to deliver high quality care and as a result, enhanced clinical outcomes for their patients. our products are technological leaders in the specialties that we serve: orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. conmed's mission, and the focus of every employee around the world, is to improve the quality of health care by designing, producing and marketing innovative, high-quality products. our emphasis is on our customer’s satisfaction and on our enhanced patient outcomes. we strive to demonstrate thoughtful leadership, provide meaningful opportunities for employees, and be a responsible member of the local communities in which we conduct business. conmed is headquartered in beautiful, upstate new york (utica), and employs approximately 3500

Organization	Conmed Corp
Employees	4000
CEO	Mr. Curt R. Hartman
Industry	Health Technology

Management People of Conmed Corp

Name	Title
Mr. Curt R. Hartman	President, CEO & Director
Mr. Todd W. Garner CPA	Executive VP, CFO & Principal Accounting Officer
Mr. Patrick J. Beyer	Chief Operating Officer
Mr. Richard Glaze	Chief Information Officer
Hollie Foust	General Counsel & Corporate Secretary
Mr. Peter K. Shagory	Executive Vice President of Strategy & Corporate Development
Ms. Shanna L. Cotti-Osmanski	Executive VP of Information Technology & CIO
Mr. John Ferrell	Executive Vice President of Human Resources
Mr. David R. Murray	President of ConMed Electrosurgery
Ms. Kimberly A. Lockwood	Interim Corporate Controller

Important FAQs about investing in Conmed Corp from India :

What is Conmed Corp share price today?

Conmed Corp (CNMD) share price today is $74.69.

Can Indians buy Conmed Corp shares?

Yes, Indians can invest in the Conmed Corp (CNMD) from India.

With INDmoney, you can buy Conmed Corp at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Conmed Corp at zero transaction cost.

How can I buy Conmed Corp shares from India?

It is very easy to buy Conmed Corp from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Conmed Corp be purchased?

Yes, you can buy fractional shares of Conmed Corp with INDmoney app.

What are the documents required to start investing in Conmed Corp stocks?

To start investing in Conmed Corp, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.